Acrivon Therapeutics (ACRV) Expected to Release Quarterly Earnings on Thursday

Key Points

• Acrivon Therapeutics is expected to report Q3 2026 results on November 12, with analysts forecasting a loss of $0.45 per share and revenue of $0.50 million.
• In its prior quarter, the company reported a $0.43-per-share loss, beating consensus estimates of a $0.50 loss by $0.07.
• Analysts’ consensus rating is “Moderate Buy,” with a $13.50 price target; three analysts rate the stock Buy and one rates it Sell.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) is projected to post its Q3 2026 resultson Thursday, November 12th. Analysts expect Acrivon Therapeutics to announce earnings of ($0.45) per share and revenue of $0.50 million for the quarter. Investors may visit the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.50) by $0.07. On average, analysts expect Acrivon Therapeutics to post ($1.76) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Acrivon Therapeutics Trading Up 4.2%

Shares of ACRV stock opened at $1.74 on Thursday. Acrivon Therapeutics has a 1-year low of $1.27 and a 1-year high of $3.56. The stock has a market cap of $74.56 million, a price-to-earnings ratio of -0.93 and a beta of 1.96. The stock has a 50-day moving average of $1.91 and a 200-day moving average of $1.76.

Insider Transactions at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the business's stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total value of $31,019.56. Following the transaction, the chief executive officer owned 2,230,052 shares in the company, valued at $4,928,414.92. The trade was a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,345 shares of company stock valued at $37,578 in the last quarter. 10.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ACRV has been the topic of several analyst reports. Wall Street Zen upgraded Acrivon Therapeutics from a "sell" rating to a "hold" rating in a report on Monday, October 5th. Weiss Ratings raised shares of Acrivon Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 9th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Acrivon Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $13.50.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its proprietary OncoSignature platform to identify tumor characteristics that may predict a patient's response to a particular therapy, with the goal of matching treatments to the patients most likely to benefit.

Acrivon's lead investigational product is ACR-368, an oral small-molecule therapy designed to target cell-cycle checkpoint mechanisms that cancer cells rely on for survival.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.